BPC-157 at $350: what the peptide hype leaves out

What did @markusfit actually say?

Markus made several distinct claims: that Peptide Sciences shut down because they were "flying too close to the sun" and likely rebranded; that RFK's removal of peptides from Category 2 status will drive compounding pharmacies back into the market; that this regulatory shift will cause prices to "skyrocket" as Big Pharma moves in; and that RC (research chemical) companies have maybe "two to four years" left before pharmaceutical interests shut them down. He also disclosed, at the end, that he is personally launching both a clinic and an RC company, which he framed as making him uniquely unbiased.

That last point deserves a flag right away. Someone who profits from both sides of the market he's describing is not a neutral observer. That doesn't make everything he said wrong, but the "unbiased" framing is a stretch, and viewers should factor that in.

Does the science back this up?

The regulatory framing is partially grounded in real events, but the science-adjacent claims about peptides being accessible and safe outside clinical settings are where things get shaky. There is no robust clinical trial data supporting BPC-157 use in humans at all.

BPC-157 has shown promising results in animal models, including accelerated tendon healing (Sikiric et al., 2018, Current Pharmaceutical Design) and gastroprotective effects in rodents, but no Phase II or Phase III human trials exist as of 2024. The jump from rat studies to "people can afford these compounds" implies these are proven, ready-to-use therapeutics. They are not. Compounding pharmacies operating under 503A or 503B frameworks are regulated by state boards and the FDA. RC companies selling peptides labeled "not for human use" operate in a legal gray zone that does not carry the same safety oversight. Equating access through RC companies with access through compounding pharmacies is a false equivalence that conveniently serves Markus's business interests.

What did they get wrong (or right)?

He got the regulatory direction roughly right. The FDA's Category 2 bulk drug substance list has been a real battleground for peptides like BPC-157, TB-500, and others. RFK Jr.'s stated interest in loosening compounding restrictions is documented, though the actual policy outcomes are still uncertain as of mid-2025.

Where he goes wrong is the implied safety and efficacy equivalence. Saying people "can afford these peptides" from RC companies as if that's straightforwardly good ignores that RC peptides are sold without dosing validation, sterility guarantees equivalent to pharmaceutical standards, or pharmacist oversight. A 2022 analysis published in JAMA found that compounded drugs varied significantly in potency and sterility compared to FDA-approved equivalents, and RC products have even less oversight than compounded ones.

The "Big Pharma is coming to shut them down" narrative is also speculative. Pharmaceutical companies don't typically lobby to eliminate markets they haven't entered yet. The more likely regulatory pressure comes from FDA enforcement priorities, not industry conspiracy.

What should you actually know?

If you're considering peptides, the regulatory environment genuinely is shifting, and that matters for access and cost. But "access" and "safety" are not the same thing. Here's what the evidence actually supports:

• BPC-157 has no approved human trials. Animal data is interesting, not conclusive.
• Compounding pharmacies operating legally under USP 797 standards provide more sterility oversight than RC suppliers, full stop.
• The FDA's bulk drug substance list determinations affect what compounding pharmacies can legally use, not what RC companies sell, because RC companies don't claim to be pharmacies.
• Price increases following regulatory tightening are a real and documented pattern. The semaglutide shortage and subsequent compounding crackdown drove prices up significantly in 2024.
• Anyone selling you the idea that they can be unbiased while personally profiting from both the clinic and RC sides of this market is asking for a lot of trust.

Talk to a licensed prescriber who specializes in peptide therapy before sourcing anything from an RC company. The risk isn't just legal. Improperly reconstituted or contaminated peptides carry real infection risk.

Bottom line on the regulatory claims

Markus is directionally correct that the peptide market is in flux and that compounding pharmacy access is expanding under current political conditions. His two-to-four-year timeline for RC companies is a guess dressed up as insider knowledge. The "Big Pharma conspiracy" framing adds drama without evidence. And his business conflict of interest should have been disclosed at the start of the video, not buried at the end as a credibility badge.